SPRINGWORKS THERAPEUTICS, INC. (SWTX): Price and Financial Metrics


SPRINGWORKS THERAPEUTICS, INC. (SWTX): $35.22

-2.62 (-6.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SWTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SWTX POWR Grades


  • Value is the dimension where SWTX ranks best; there it ranks ahead of 45.68% of US stocks.
  • The strongest trend for SWTX is in Growth, which has been heading down over the past 178 days.
  • SWTX ranks lowest in Sentiment; there it ranks in the 5th percentile.

SWTX Stock Summary

  • SWTX's went public 2.46 years ago, making it older than just 5.84% of listed US stocks we're tracking.
  • With a price/sales ratio of 75.44, SpringWorks Therapeutics Inc has a higher such ratio than 97.05% of stocks in our set.
  • SWTX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 5.67% of US stocks.
  • Stocks that are quantitatively similar to SWTX, based on their financial statements, market capitalization, and price volatility, are RESN, FREQ, ACRS, AKTS, and RETA.
  • SWTX's SEC filings can be seen here. And to visit SpringWorks Therapeutics Inc's official web site, go to www.springworkstx.com.

SWTX Valuation Summary

  • SWTX's price/sales ratio is 105.4; this is 828.63% higher than that of the median Healthcare stock.
  • SWTX's price/earnings ratio has moved down 7.6 over the prior 24 months.
  • SWTX's price/earnings ratio has moved down 7.6 over the prior 24 months.

Below are key valuation metrics over time for SWTX.

Stock Date P/S P/B P/E EV/EBIT
SWTX 2021-08-31 105.4 7.4 -42.3 -41.4
SWTX 2021-08-30 107.7 7.6 -43.2 -42.3
SWTX 2021-08-27 111.0 7.8 -44.5 -43.6
SWTX 2021-08-26 107.4 7.6 -43.1 -42.1
SWTX 2021-08-25 110.9 7.8 -44.5 -43.6
SWTX 2021-08-24 107.8 7.6 -43.3 -42.3

SWTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SWTX has a Quality Grade of D, ranking ahead of 14.5% of graded US stocks.
  • SWTX's asset turnover comes in at 0.072 -- ranking 285th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows SWTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.072 1 -0.239
2021-03-31 0.081 1 -0.217
2020-12-31 0.095 1 -0.275
2020-09-30 0.000 NA -1.198
2020-06-30 0.000 NA -5.408

SWTX Price Target

For more insight on analysts targets of SWTX, see our SWTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $114.80 Average Broker Recommendation 1.42 (Moderate Buy)

SWTX Stock Price Chart Interactive Chart >

Price chart for SWTX

SWTX Price/Volume Stats

Current price $35.22 52-week high $89.75
Prev. close $37.84 52-week low $33.33
Day low $34.88 Volume 882,600
Day high $37.53 Avg. volume 474,675
50-day MA $51.37 Dividend yield N/A
200-day MA $61.71 Market Cap 1.74B

SPRINGWORKS THERAPEUTICS, INC. (SWTX) Company Bio


Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.


SWTX Latest News Stream


Event/Time News Detail
Loading, please wait...

SWTX Latest Social Stream


Loading social stream, please wait...

View Full SWTX Social Stream

Latest SWTX News From Around the Web

Below are the latest news stories about SpringWorks Therapeutics Inc that investors may wish to consider to help them evaluate SWTX as an investment opportunity.

SpringWorks Therapeutics GAAP EPS of -$1.15

SpringWorks Therapeutics press release (SWTX): Q4 GAAP EPS of -$1.15.Cash, cash equivalents and marketable securities were $432.7 million as of December 31, 2021.

Seeking Alpha | February 24, 2022

SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights

– Topline Analysis from Phase 3 DeFi Trial Expected to be Triggered in the First Quarter of 2022; Topline Data Expected to be Reported During the First Half of 2022 – – Expanded Collaboration with GlaxoSmithKline to Include Two New Sub-Studies Evaluating the Combination of Nirogacestat Plus BLENREP with Standard-of-Care Multiple Myeloma Therapies; Initial Clinical Data from Ongoing Study Expected Mid-Year – – Further Advanced Broad, Non-Exclusive Strategy to Evaluate Nirogacestat as a Potential

Yahoo | February 24, 2022

8 Medical Stocks to Buy According to Mitchell Blutt’s Consonance Capital

In this article, we will be looking at the 8 medical stocks to buy according to Mitchell Blutt’s Consonance Capital. You can skip our detailed analysis of these stocks and head directly to 3 Medical Stocks to Buy According to Mitchell Blutt’s Consonance Capital. Mitchell Blutt is an American physician-businessman. He is one of the […]

Yahoo | February 15, 2022

CIBC Asset Management Inc Buys Bank of Nova Scotia, Franco-Nevada Corp, Suncor Energy Inc, ...

Toronto, A6, based Investment company CIBC Asset Management Inc (Current Portfolio) buys Bank of Nova Scotia, Franco-Nevada Corp, Suncor Energy Inc, NVIDIA Corp, iShares MSCI EAFE ETF, sells Shaw Communications Inc, Progressive Corp, Visa Inc, Allegion PLC, Lightspeed Commerce Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, CIBC Asset Management Inc.

Yahoo | February 8, 2022

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

STAMFORD, Conn., Feb. 01, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will present at the following upcoming investor conferences: 2022 Guggenheim Oncology Conference on Thursday, February 10 from 10:00-10:25 am ET.Cowen 42nd Annual Health Care Conference on Monday, March 7 from 1:30-2:00 pm ET.Barc

Yahoo | February 1, 2022

Read More 'SWTX' Stories Here

SWTX Price Returns

1-mo -30.49%
3-mo -36.65%
6-mo -50.30%
1-year -52.32%
3-year N/A
5-year N/A
YTD -43.18%
2021 -14.53%
2020 88.41%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5642 seconds.